OTC
0.00USD
0.00 (0.00%)
We have scored 7 news catalysts on Anthera Pharmaceuticals, Inc. (ANTH) over the past 12 months. The biggest single-day move next to one of them came Jul 12, 2026, when ANTH closed −0.0%: “The leaders responsible for keeping OpenAI's AI safe keep leaving”. Coverage across the window leans positive (average ticker sentiment +0.53). Most of the impact sits in sector technology and eps growth rate.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.6K
P/E
—
EPS
—
Beta
-5.88
52W range
0.0001-0.001
Day range
0.00–0.00
Open
0.00
Prev close
0.00
Volume
23.9K
Avg volume
2.3K
Dividend
0.00
IPO
2010-03-01
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Anthera Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Anthera Pharmaceuticals, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for ANTH: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
